• 1
    Centers for Disease Control and Prevention (CDC). Update: novel influenza A (H1N1) virus infections–worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 4538.
  • 2
    Scalera NM, Mossad SB. The first pandemic of the 21st century: a review of the 2009 pandemic variant influenza A (H1N1) virus. Postgrad Med 2009; 121: 437.
  • 3
    Jain R, Goldman RD. Novel influenza A (H1N1): clinical presentation, diagnosis, and management. Pediatr Emerg Care 2009; 25: 7916.
  • 4
    Centers for Disease Control and Prevention (CDC). Deaths and hospitalizations related to 2009 pandemic influenza A (H1N1): Greece, May 2009–February 2010. MMWR Morb Mortal Wkly Rep 2010; 59: 6826.
  • 5
    Koegelenberg CF, Irusen EM, Cooper R, Diacon AH, Taljaard JJ, Mowlana A, et al. High mortality from respiratory failure secondary to swine-origin influenza A (H1N1) in South Africa. QJM 2010; 103: 31925.
  • 6
    Lu W, Tambyah PA. Safety and immunogenicity of influenza A H1N1 vaccines. Expert Rev Vaccines 2010; 9: 3659.
  • 7
    Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O'Fallon WM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48: 548.
  • 8
    Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls. Arthritis Rheum 2002; 46: 228793.
  • 9
    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 227585.
  • 10
    Gluck T, Muller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis 2008; 46: 145965.
  • 11
    Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010; 39: 4427.
  • 12
    Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF-α blockers. Ann Rheum Dis 2006; 65: 1914.
  • 13
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 14
    Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 15
    Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, and the CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 266573.
  • 16
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 3618.
  • 17
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 18
    Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005; 19: 685706.
  • 19
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 228691.
  • 20
    Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonization of requirements for influenza vaccines. 1997. URL:
  • 21
    Committee for Proprietary Medicinal Products (CPMC). Concept paper on the revision of the CPMP/BWP note for guidance on harmonization of requirements for influenza vaccines. 2001. CPMP/EPW/1045/01.
  • 22
    Palmer DF, Coleman MT, Dowdle WR, Schild DC. Advanced laboratory techniques for influenza diagnosis. Washington, DC: US Department of Health, Education and Welfare; 1975.
  • 23
    Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, et al. The effect of anti-tumour necrosis factor α treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008; 67: 7136.
  • 24
    Del Porto F, Lagana B, Biselli R, Donatelli I, Campitelli L, Nisini R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis: safety and immunogenicity. Vaccine 2006; 24: 321723.
  • 25
    Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008; 67: 93741.
  • 26
    Van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62: 7581.
  • 27
    Holvast A, Huckriede A, Wilschut J, Horst G, De Vries JJ, Benne CA, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006; 65: 9138.
  • 28
    Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 2002; 29: 25557.
  • 29
    Kling MC, Larian AA, Scordi-Bello I, Emer J, Lebwohl MG. Fatal influenza A (H1N1) respiratory tract infection in a patient having psoriasis treated with infliximab. Arch Dermatol 2010; 146: 6514.
  • 30
    Camous L, Lemiale V, Canet E, Max A, Schnell D, Le Goff J, et al. Clinical features of H1N1 2009 infection in critically ill immunocompromised patients. Crit Care 2010; 14: 139.
  • 31
    Kumar D, Michaels MG, Morris MI, Green M, Avery RK, Liu C, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10: 5216.
  • 32
    Tebas P, Frank I, Lewis M, Quinn J, Zifchak L, Thomas A, et al, for the Center for AIDS Research and Clinical Trials Unit of the University of Pennsylvania. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010; 24: 218792.
  • 33
    Bickel M, Wieters I, Khaykin P, Nisius G, Haberl A, Stephan C, et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010; 24: F315.
  • 34
    Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus 2009; 18: 121725.
  • 35
    Lippi G, Targher G, Franchini M. Vaccination, squalene and anti-squalene antibodies: facts or fiction? Eur J Intern Med 2010; 21: 703.